JP2009536218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536218A5 JP2009536218A5 JP2009510100A JP2009510100A JP2009536218A5 JP 2009536218 A5 JP2009536218 A5 JP 2009536218A5 JP 2009510100 A JP2009510100 A JP 2009510100A JP 2009510100 A JP2009510100 A JP 2009510100A JP 2009536218 A5 JP2009536218 A5 JP 2009536218A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- halogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 69
- 229910052739 hydrogen Inorganic materials 0.000 claims description 48
- 239000001257 hydrogen Substances 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 44
- 150000002367 halogens Chemical class 0.000 claims description 44
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 22
- 229940002612 prodrugs Drugs 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- -1 hydroxy, amino Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000001732 thrombotic Effects 0.000 claims description 4
- 210000004369 Blood Anatomy 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002383 Angina pectoris Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 208000002528 Coronary Thrombosis Diseases 0.000 claims description 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims description 2
- 206010014498 Embolic stroke Diseases 0.000 claims description 2
- 210000003709 Heart Valves Anatomy 0.000 claims description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims description 2
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010043647 Thrombotic stroke Diseases 0.000 claims description 2
- 206010044390 Transient ischaemic attack Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 201000005114 blood coagulation disease Diseases 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 238000009434 installation Methods 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 230000000414 obstructive Effects 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 230000002537 thrombolytic Effects 0.000 claims description 2
- 201000007023 thrombotic thrombocytopenic purpura Diseases 0.000 claims description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 0 *C(NCc(nc1*)c(*)[n]1-c(cc1*)c(*)cc1S)=O Chemical compound *C(NCc(nc1*)c(*)[n]1-c(cc1*)c(*)cc1S)=O 0.000 description 12
- 206010009802 Coagulopathy Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- MEJIGHZPRMKCHW-UHFFFAOYSA-N CC(C)N(C=CN=C1)C1=O Chemical compound CC(C)N(C=CN=C1)C1=O MEJIGHZPRMKCHW-UHFFFAOYSA-N 0.000 description 1
- VZWZDYSMVHQTHD-UHFFFAOYSA-N CC(C)N1N=CC=CC1=O Chemical compound CC(C)N1N=CC=CC1=O VZWZDYSMVHQTHD-UHFFFAOYSA-N 0.000 description 1
- LQKMCBPMBNUKSU-UHFFFAOYSA-N CN(C=CC=N1)C1=O Chemical compound CN(C=CC=N1)C1=O LQKMCBPMBNUKSU-UHFFFAOYSA-N 0.000 description 1
- GGYVTHJIUNGKFZ-UHFFFAOYSA-N CN(CCCC1)C1=O Chemical compound CN(CCCC1)C1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
- COYPZADTXISTSJ-UHFFFAOYSA-N CN(CCCN1)C1=O Chemical compound CN(CCCN1)C1=O COYPZADTXISTSJ-UHFFFAOYSA-N 0.000 description 1
- JTPZTKBRUCILQD-UHFFFAOYSA-N CN(CCN1)C1=O Chemical compound CN(CCN1)C1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 description 1
- HOURFTFBPLQQTA-UHFFFAOYSA-N COC(c(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1)=O Chemical compound COC(c(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1)=O HOURFTFBPLQQTA-UHFFFAOYSA-N 0.000 description 1
- VUZDBGMBMPEGLU-UHFFFAOYSA-N CS(c(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1)(=O)=O Chemical compound CS(c(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1)(=O)=O VUZDBGMBMPEGLU-UHFFFAOYSA-N 0.000 description 1
- AWRRWVACWCKVAB-UHFFFAOYSA-N CSc1nc(CNC(c([s]2)ccc2Cl)=O)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O Chemical compound CSc1nc(CNC(c([s]2)ccc2Cl)=O)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O AWRRWVACWCKVAB-UHFFFAOYSA-N 0.000 description 1
- AWRRWVACWCKVAB-UHFFFAOYSA-O C[SH+]c1nc(CNC(c([s]2)ccc2Cl)=O)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O Chemical compound C[SH+]c1nc(CNC(c([s]2)ccc2Cl)=O)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O AWRRWVACWCKVAB-UHFFFAOYSA-O 0.000 description 1
- QZWFIJCOFXOLBT-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O QZWFIJCOFXOLBT-UHFFFAOYSA-N 0.000 description 1
- FMRVZCFQPFDOBB-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(CCS(C1)(=O)=O)C1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(CCS(C1)(=O)=O)C1=O FMRVZCFQPFDOBB-UHFFFAOYSA-N 0.000 description 1
- KIVALIXZTZZARM-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(CCS(C1)=O)C1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(CCS(C1)=O)C1=O KIVALIXZTZZARM-UHFFFAOYSA-N 0.000 description 1
- CJGVACPFTXQBCJ-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(CCSC1)C1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1)ccc1N(CCSC1)C1=O CJGVACPFTXQBCJ-UHFFFAOYSA-N 0.000 description 1
- CRUMWEIFBNZNPN-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1F)ccc1N(C=CC=C1)C1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(cc1F)ccc1N(C=CC=C1)C1=O CRUMWEIFBNZNPN-UHFFFAOYSA-N 0.000 description 1
- RQSYBZQWMSQDFK-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1F Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1F RQSYBZQWMSQDFK-UHFFFAOYSA-N 0.000 description 1
- WIMLENNNCRQYLE-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1N(CC1)CCS1(=O)=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1N(CC1)CCS1(=O)=O WIMLENNNCRQYLE-UHFFFAOYSA-N 0.000 description 1
- LUGWMEWUBXERDW-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1N(CCN1)CC1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1N(CCN1)CC1=O LUGWMEWUBXERDW-UHFFFAOYSA-N 0.000 description 1
- XBFQEWMEELMQKX-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1N1CCSCC1 Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1)c[n]1-c(ccc(N(C=CC=C1)C1=O)c1)c1N1CCSCC1 XBFQEWMEELMQKX-UHFFFAOYSA-N 0.000 description 1
- ZTMZOKIEPBNNST-UHFFFAOYSA-N O=C(c([s]1)ccc1Cl)NCc(nc1S=O)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O Chemical compound O=C(c([s]1)ccc1Cl)NCc(nc1S=O)c[n]1-c(cc1)ccc1N(C=CC=C1)C1=O ZTMZOKIEPBNNST-UHFFFAOYSA-N 0.000 description 1
- KMANCAXITPTEII-UHFFFAOYSA-N OCCNc(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1 Chemical compound OCCNc(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1 KMANCAXITPTEII-UHFFFAOYSA-N 0.000 description 1
- GEIVFFPHNYQVML-UHFFFAOYSA-N OS(CCCCNc(cc1)ccc1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1)O Chemical compound OS(CCCCNc(cc1)ccc1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1)O GEIVFFPHNYQVML-UHFFFAOYSA-N 0.000 description 1
- MHVQVYXOJMLSMZ-UHFFFAOYSA-N Oc(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1 Chemical compound Oc(cc(cc1)N(C=CC=C2)C2=O)c1-[n]1cnc(CNC(c([s]2)ccc2Cl)=O)c1 MHVQVYXOJMLSMZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79795406P | 2006-05-05 | 2006-05-05 | |
| US60/797,954 | 2006-05-05 | ||
| US88366707P | 2007-01-05 | 2007-01-05 | |
| US60/883,667 | 2007-01-05 | ||
| PCT/US2007/068262 WO2007131179A1 (en) | 2006-05-05 | 2007-05-04 | Factor xa inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536218A JP2009536218A (ja) | 2009-10-08 |
| JP2009536218A5 true JP2009536218A5 (US07585860-20090908-C00112.png) | 2011-05-26 |
| JP5227311B2 JP5227311B2 (ja) | 2013-07-03 |
Family
ID=38480433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510100A Expired - Fee Related JP5227311B2 (ja) | 2006-05-05 | 2007-05-04 | 第Ｘａ因子阻害剤 |
Country Status (17)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| CN1968922A (zh) | 2004-06-18 | 2007-05-23 | 米伦纽姆医药公司 | 因子xa抑制剂 |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| SI1928454T1 (sl) | 2005-05-10 | 2015-01-30 | Intermune, Inc. | Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema |
| US20080200431A1 (en) * | 2005-07-08 | 2008-08-21 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| WO2007008143A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| WO2007112367A2 (en) * | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
| WO2007131179A1 (en) | 2006-05-05 | 2007-11-15 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| ES2382055T3 (es) * | 2006-11-02 | 2012-06-04 | Millennium Pharmaceuticals, Inc. | Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa |
| AU2008205093A1 (en) * | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| KR101473207B1 (ko) * | 2007-04-13 | 2014-12-16 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법 |
| US20080279845A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| WO2009063029A2 (en) * | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Substituted amides, manufacturing and use thereof as medicaments |
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| US20110160250A1 (en) * | 2009-12-17 | 2011-06-30 | Millennium Pharmaceuticals, Inc. | Crystalline forms of a factor xa inhibitor |
| CN104774176A (zh) | 2009-12-17 | 2015-07-15 | 米伦纽姆医药公司 | 合成Xa因子抑制剂的方法 |
| JP5796872B2 (ja) * | 2009-12-17 | 2015-10-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 第Ｘａ因子阻害剤の結晶性塩 |
| US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| AR082804A1 (es) | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Formas cristalinas de un inhibidor del factor xa |
| TW201240664A (en) | 2010-09-01 | 2012-10-16 | Portola Pharm Inc | Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor |
| US20150224091A1 (en) | 2011-08-31 | 2015-08-13 | Portola Pharmaceuticals, Inc. | Prevention and treatment of thrombosis in medically ill patients |
| CN103242310A (zh) * | 2012-02-10 | 2013-08-14 | 苏州迈泰生物技术有限公司 | 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途 |
| MX2015000830A (es) * | 2012-07-18 | 2015-10-26 | Sunshine Lake Pharma Co Ltd | Derivados heterociclicos nitrogenosos y su aplicacion en farmacos. |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| DK3165232T3 (da) * | 2012-12-24 | 2019-09-16 | Coagulant Therapeutics Corp | Faktor vii-polypeptider med kortvarig virkning |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| ES2663806T3 (es) | 2013-12-19 | 2018-04-17 | unshine Lake Pharma Co., Ltd. | Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| EP3197873B1 (de) * | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| EP3271332A1 (de) * | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| ES2744775T3 (es) | 2015-07-06 | 2020-02-26 | Bayer Cropscience Ag | Heterociclos que contienen nitrógeno como pesticidas |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| US10148678B2 (en) | 2015-10-01 | 2018-12-04 | The Boeing Company | Cybersecurity system with differentiated capacity to deal with complex cyber attacks |
| CN108430976B (zh) * | 2015-12-16 | 2022-07-05 | 日本曹达株式会社 | 芳基唑化合物和有害生物防除剂 |
| CN105753804A (zh) * | 2016-04-15 | 2016-07-13 | 大连信科化工有限公司 | 一种制备3-吗啉酮的方法 |
| WO2019105871A1 (de) | 2017-11-29 | 2019-06-06 | Bayer Aktiengesellschaft | Stickstoffhaltige heterocyclen als schädlingsbekämpfungsmittel |
| WO2019215076A1 (de) * | 2018-05-08 | 2019-11-14 | Bayer Aktiengesellschaft | Verfahren zur herstellung stickstoffhaltiger heterocyclen |
| CN108715584B (zh) * | 2018-06-22 | 2021-06-25 | 四川大学华西医院 | 以n-吡啶-2-(1h)-腈亚氨为母核的荧光分子及其制备与应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US186810A (en) * | 1877-01-30 | Improvement in machines for making metal fellies | ||
| US298806A (en) * | 1884-05-20 | Bag and twine holder | ||
| US279845A (en) * | 1883-06-19 | John d | ||
| US171358A (en) * | 1875-12-21 | Improvement in machines for trimming and punching roofing-slates | ||
| US749217A (en) * | 1904-01-12 | Ho model | ||
| US254036A (en) * | 1882-02-21 | Measuring-faucet | ||
| US162690A (en) * | 1875-04-27 | Improvement in valves for steam-engines | ||
| US125052A (en) * | 1872-03-26 | Improvement in apparatus for checking horses | ||
| US153876A (en) * | 1874-08-04 | Improvement in carbureting apparatus | ||
| US66615A (en) * | 1867-07-09 | Steering apparatus | ||
| US100193A (en) * | 1870-02-22 | John ross | ||
| US241233A (en) * | 1881-05-10 | Wind-wheel | ||
| US112039A (en) * | 1871-02-21 | Improvement in plow-colters | ||
| US98119A (en) * | 1869-12-21 | Improved rocking and easy chair | ||
| US197929A (en) * | 1877-12-11 | Improvement in boots and shoes | ||
| US63113A (en) * | 1867-03-19 | smith | ||
| US42015A (en) * | 1864-03-22 | Improvement in saddles | ||
| US259924A (en) * | 1882-06-20 | Sand-band | ||
| US29064A (en) * | 1860-07-10 | Lowering and detaching ships boats | ||
| US51578A (en) * | 1865-12-19 | Improvement in cigar-machines | ||
| US293704A (en) * | 1884-02-19 | Windmill | ||
| US185092A (en) * | 1876-12-05 | Improvement in check-rowers | ||
| US697135A (en) * | 1901-03-07 | 1902-04-08 | Henry W Scott | Antislipping device. |
| US756037A (en) * | 1903-03-21 | 1904-03-29 | Angus Morrison | Press-rack. |
| US836536A (en) * | 1906-02-12 | 1906-11-20 | Eagle Lock Co | Suit-case lock. |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| JP2001513502A (ja) | 1997-08-11 | 2001-09-04 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ５，６−ヘテロアリールジピリド［２，３−ｂ：３’，２’−ｆ］アゼピン類及びＨＩＶ感染の予防及び治療におけるそれらの使用 |
| GB9725244D0 (en) | 1997-11-29 | 1998-01-28 | Zeneca Ltd | Chemical compounds |
| US6644367B1 (en) * | 1999-07-23 | 2003-11-11 | Scholle Corporation | Connector assembly for fluid flow with rotary motion for connection and disconnection |
| WO2001019788A2 (en) | 1999-09-17 | 2001-03-22 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| ATE368643T1 (de) | 2001-03-30 | 2007-08-15 | Millennium Pharm Inc | Faktor xa benzamidin inhibitoren |
| US7312235B2 (en) | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| ES2180456B1 (es) | 2001-07-20 | 2004-05-01 | Laboratorios S.A.L.V.A.T., S.A. | Isoxazoles sustituidos y su utilizacion como antibioticos. |
| US6914058B2 (en) | 2002-01-18 | 2005-07-05 | Dr. Reddy's Laboratories, Limited | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
| US20050171358A1 (en) | 2002-03-07 | 2005-08-04 | Noriko Shimozono | Substituted isoxazole alkylamine derivative and agri-and horticultural fungicide |
| JP3090812U (ja) * | 2002-06-18 | 2002-12-26 | アルプス電気株式会社 | 高周波モジュール |
| WO2004101531A1 (en) | 2003-04-29 | 2004-11-25 | Dr. Reddy's Laboratories Ltd. | Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE10322469A1 (de) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| WO2004106329A2 (en) | 2003-06-03 | 2004-12-09 | Dr. Reddy's Laboratories Ltd. | Novel antiinfective compounds and their pharmaceutical compositions |
| US7199149B2 (en) * | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
| CA2541809A1 (en) | 2003-10-09 | 2005-04-21 | Millennium Pharmaceuticals, Inc. | Thioether-substituted benzamides as inhibitors of factor xa |
| WO2005035528A2 (en) | 2003-10-14 | 2005-04-21 | Dr. Reddy's Laboratories Ltd. | Triazole derivatives as antibacterial agents |
| WO2005082892A2 (en) | 2004-02-17 | 2005-09-09 | Dr. Reddy's Laboratories Ltd. | Triazole compounds as antibacterial agents and pharmaceutical compositions containing them |
| US7696352B2 (en) | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| CN1968922A (zh) | 2004-06-18 | 2007-05-23 | 米伦纽姆医药公司 | 因子xa抑制剂 |
| DE102004031258A1 (de) * | 2004-06-29 | 2006-02-09 | Jennissen, Herbert P., Prof. Dr. | Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen |
| US20060002099A1 (en) * | 2004-06-30 | 2006-01-05 | Stoneham Edward B | Electromagnetic shield assembly |
| WO2006083924A1 (en) | 2005-02-02 | 2006-08-10 | Vitae Pharmaceuticals, Inc. | 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| AR057976A1 (es) * | 2005-08-29 | 2008-01-09 | Boehringer Ingelheim Int | Biarilos sustituidos y su uso como medicamentos. |
| KR101423483B1 (ko) | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| BRPI0618362A2 (pt) | 2005-11-08 | 2011-08-30 | Millennium Pharm Inc | sais farmacêuticos inovadores e polimorfos de um inibidor de fator xa |
| WO2007112367A2 (en) | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
| WO2007131179A1 (en) | 2006-05-05 | 2007-11-15 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| DE102006025314A1 (de) | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Arylsubstituierte Heterozyklen und ihre Verwendung |
| US20080051578A1 (en) | 2006-08-24 | 2008-02-28 | Georg Dahmann | Substituted biaryls, process for their manufacture and use thereof as medicaments |
| ES2382055T3 (es) | 2006-11-02 | 2012-06-04 | Millennium Pharmaceuticals, Inc. | Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa |
| PT2101760E (pt) | 2006-12-08 | 2013-05-07 | Millennium Pharm Inc | Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa |
| AU2008205093A1 (en) | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| WO2008121721A2 (en) | 2007-03-28 | 2008-10-09 | Portola Pharmaceuticals, Inc. | Targeted delivery and expression of procoagulant hemostatic activity |
| KR101473207B1 (ko) | 2007-04-13 | 2014-12-16 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법 |
| US20080279845A1 (en) | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| BRPI0816837B1 (pt) | 2007-09-28 | 2022-10-18 | Portola Pharmaceuticals, Inc | Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica |
| WO2010056765A2 (en) | 2008-11-14 | 2010-05-20 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| ES2607935T3 (es) | 2009-03-30 | 2017-04-04 | Portola Pharmaceuticals, Inc. | Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos |
| CA2767858C (en) | 2009-07-15 | 2019-02-12 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
-
2007
- 2007-05-04 WO PCT/US2007/068262 patent/WO2007131179A1/en active Application Filing
- 2007-05-04 AU AU2007247928A patent/AU2007247928B2/en not_active Ceased
- 2007-05-04 NZ NZ572418A patent/NZ572418A/en not_active IP Right Cessation
- 2007-05-04 CN CN200780015911XA patent/CN101490036B/zh not_active Expired - Fee Related
- 2007-05-04 US US11/744,735 patent/US7763608B2/en not_active Expired - Fee Related
- 2007-05-04 EA EA200802288A patent/EA015942B1/ru not_active IP Right Cessation
- 2007-05-04 BR BRPI0711296-3A patent/BRPI0711296A2/pt not_active Application Discontinuation
- 2007-05-04 TW TW096115906A patent/TW200813017A/zh unknown
- 2007-05-04 MX MX2008014193A patent/MX2008014193A/es active IP Right Grant
- 2007-05-04 KR KR1020087029729A patent/KR20090010098A/ko not_active Application Discontinuation
- 2007-05-04 JP JP2009510100A patent/JP5227311B2/ja not_active Expired - Fee Related
- 2007-05-04 AR ARP070101952A patent/AR060768A1/es unknown
- 2007-05-04 EP EP07761905.4A patent/EP2016072B1/en active Active
- 2007-05-04 CA CA002651303A patent/CA2651303A1/en not_active Abandoned
-
2008
- 2008-07-02 US US12/166,944 patent/US7767697B2/en not_active Expired - Fee Related
- 2008-10-23 IL IL194891A patent/IL194891A/en active IP Right Grant
- 2008-10-31 ZA ZA2008/09362A patent/ZA200809362B/en unknown
-
2009
- 2009-06-16 HK HK09105366.6A patent/HK1126490A1/xx not_active IP Right Cessation
-
2010
- 2010-05-11 US US12/777,956 patent/US8063077B2/en not_active Expired - Fee Related
- 2010-10-05 ZA ZA2010/07095A patent/ZA201007095B/en unknown
-
2011
- 2011-10-10 US US13/270,170 patent/US8349873B2/en not_active Expired - Fee Related
